Drug discovery for malaria: a very challenging and timely endeavor.
The prevalence of resistance to known antimalarial drugs has resulted in the expansion of antimalarial drug discovery efforts. Academic and nonprofit institutions are partnering with the pharmaceutical industry to develop new antimalarial drugs. Several new antimalarial agents are undergoing clinical trials, mainly those resurrected from previous antimalarial drug discovery programs. Novel antimalarials are being advanced through the drug development process, of course, with the anticipated high failure rate typical of drug discovery. Many of these are summarized in this review. Mechanisms for funding antimalarial drug discovery and genomic information to aid drug target selection have never been better. It remains to be seen whether ongoing efforts will be sufficient for reducing malaria burden in the developing world.
Gelb
Michael H
MH
Department of Chemistry, University of Washington, Seattle, WA 98195, USA. gelb@chem.washington.edu
D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000627:therapeutic use*; D003374:Coumarins / Q000737:chemistry / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000473:pathology; D010545:Peroxides / Q000737:chemistry / Q000627:therapeutic use; D010961:Plasmodium / Q000187:drug effects*
D000962:Antimalarials; D003374:Coumarins; D010545:Peroxides; C464540:arteminin